Evidence map›Paper›PMID 40748498›Full record

ArticleExperimental brain research2025

Pericyte loss: a key factor inducing brain Aβ40 accumulation and neuronal degeneration in cerebral amyloid angiopathy.

Tao Liu, Weihong Guo, Ming Gong, Linyuan Zhu, Tingting Cao, Yilong Huang, Yunzhu Yang, Jiayi Chen, Canhong Yang, Shufen Zhang and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Experimental brain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. [Sulforaphane reduces reactive astrocyte-mediated neuron apoptosisNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tao Liu *Department of Neurology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, 510630, China.
Weihong Guo *Department of Neurology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, 510630, China.
Ming Gong *Department of Neurology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, 510630, China.
Linyuan ZhuDepartment of Neurology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, 510630, China.
Tingting CaoDepartment of Neurology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, 510630, China.
Yilong HuangDepartment of Neurology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, 510630, China.
Yunzhu YangDepartment of Neurology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, 510630, China.
Jiayi ChenDepartment of Neurology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, 510630, China.
Canhong YangDepartment of Neurology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, 510630, China.
Shufen ZhangDepartment of Internal Medicine, The Second People's Hospital of Guangzhou Nansha, Guangzhou, 510630, China.
Jiafa ZhangDepartment of Neurology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, 510630, China. 596471200@qq.com.
Tianming LüDepartment of Neurology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, 510630, China. lutianming@139.com.

Funding

Guangzhou Science and Technology Plan Project 2024A04J4728Livelihood Science and Technology Project Grant NO.2021MS003Natural Science Foundation of Guangdong Province 2017A030313461Soft Science Research Project of Guangming District, Shenzhen 2021R01017
6 · The paper itself

Abstract

Cerebral amyloid angiopathy (CAA) is a cerebral small vessel disease common among the elderly. Pericyte loss is one of the earliest characteristics of CAA. Although pericyte loss correlates with neuronal loss, the molecular mechanisms by which pericyte loss contributes to neurodegeneration and CAA progression remain poorly understood. This study aimed to explore the role and the mechanism of pericyte loss in CAA using in vivo APP/PS1 mice models and an in vitro neurovascular unit (NVU) model. The findings showed that pericyte coverage and mRNA expression levels of pleiotrophin (PTN) were significantly decreased in the brain of APP/PS1 mice compared with wild-type (WT) littermate mice, while the amyloid-beta peptide (Aβ) load was elevated. Both pericyte loss and Aβ40 fibrils increased the permeability of the blood-brain barrier (BBB) and decreased secretion of PTN in the in vitro NVU model. Notably, pericyte reintroduction attenuated Aβ40-induced apoptosis in all SH-SY5Y neuroblastoma cells across experimental models, and pericytes reversed the apoptosis of SH-SY5Y cells induced by Aβ40 fibrils in these models. Furthermore, Aβ40 fibrils downregulated PTN secretion and induced pericyte apoptosis through activation of the p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) signaling pathways. Collectively, these data suggest that BBB disruption resulting from pericyte loss serves as an early pathological hallmark in CAA, promoting Aβ40 accumulation and neurodegeneration via MAPK-dependent pathways. These findings highlight the therapeutic potential of pericyte preservation strategies in CAA management.

Indexed as

Amyloid beta-PeptidesBrainCerebral Amyloid AngiopathyNerve DegenerationPeptide FragmentsPericytesAnimalsApoptosisBlood-Brain BarrierCarrier ProteinsCytokinesDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLAmyloid beta-Peptidesamyloid beta-protein (1-40)Carrier ProteinsCytokinesPeptide FragmentspleiotrophinAmyloid-beta peptideApoptosisCerebral amyloid angiopathyNeurovascular unitPericytePleiotrophin

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.